C4 THERAPEUTICS, INC.

(CCCC)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
7.390 USD   +5.42%
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about C4 THERAPEUTICS, INC.
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluat..
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
05/16C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF..
GL
05/09HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy R..
MT
05/05C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/05C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highli..
GL
04/28Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Ris..
MT
04/18UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating
MT
04/12NORTH AMERICAN MORNING BRIEFING : Stocks Waver, -3-
DJ
04/11AACR PRESENTATION : Preclinical Evaluation of CFT1946
PU
04/11Top Midday Decliners
MT
04/11C4 Therapeutics Shares Drop After BofA Securities Downgrade
MT
04/11AACR PRESENTATION : The Discovery and Characterization of CFT7455
PU
04/11SVB Leerink Adjusts C4 Therapeutics Price Target to $25 From $40, Maintains Outperform ..
MT
04/11Stifel Adjusts C4 Therapeutics' Price Target to $15 From $28, Reiterates Hold Rating
MT
04/11BMO Capital Adjusts C4 Therapeutics' Price Target to $20 From $57, Keeps Outperform Rat..
MT
04/11BofA Securities Cuts C4 Therapeutics to Neutral From Buy, Price Target to $15 From $46
MT
04/10AACR PRESENTATION : The Discovery and Characterization of CFT8634
PU
04/08C4 Therapeutics Reports CFT7455 Clinical Trial Data -- Stock Sinks
MT
04/08TRANSCRIPT : C4 Therapeutics, Inc. - Special Call
CI
04/08C4 THERAPEUTICS : Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical T..
PU
04/08C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08AACR POSTER PRESENTATION : CFT7455 Phase 1/2 Cohort A
PU
04/08C4 THERAPEUTICS : Corporate Presentation – April 2022
PU
04/08C4 THERAPEUTICS : CFT7455 Phase 1/2 Cohort A Data Investor Call
PU
04/08C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical ..
AQ
04/08C4 Therapeutics, Inc. Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Cli..
CI
03/16C4 THERAPEUTICS : Appoints Utpal Koppikar to Board of Directors - Form 8-K
PU
03/16C4 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosur..
AQ
03/16C4 Therapeutics, Inc. Announces Resignation of Elena Prokupets as Director and Member o..
CI
03/16C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
GL
03/16C4 Therapeutics Appoints Utpal Koppikar to Board of Directors and as Chair of the Audit..
CI
03/10JPMorgan Starts C4 Therapeutics at Overweight With $43 Price Target
MT
03/09C4 Therapeutics Shares Climb 17% on FDA Drug Designation
DJ
03/09C4 Therapeutics Says FDA Grants Orphan Drug Designation for Soft Tissue Cancer Drug
MT
03/09C4 THERAPEUTICS : Cowen Healthcare Conference Presentation
PU
03/09C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of ..
AQ
03/09C4 Therapeutics Gets Orphan Drug Designation for Sarcoma Treatment
DJ
03/08C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annua..
GL
02/25Stifel Nicolaus Adjusts Price Target for C4 Therapeutics to $28 From $44, Maintains Hol..
MT
02/24C4 Therapeutics Full Year 2021 Net Loss Per Share Narrows, Revenue Rises
MT
02/24C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
02/24C4 THERAPEUTICS : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
02/24C4 THERAPEUTICS : Corporate Presentation – February 2022
PU
02/24C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
GL
02/24C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
CI
02/09Wells Fargo Starts C4 Therapeutics at Equalweight With $25 Price Target
MT
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb
MT
01/10TRANSCRIPT : C4 Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference,..
CI
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
CI
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
2021C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to NASDAQ Biotechnology Index
CI
2021C4 Therapeutics to Join NASDAQ Biotechnology Index
MT
2021C4 Therapeutics Added to NASDAQ Biotechnology Index
GL
2021C4 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
2021BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target
MT
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
PU
2021C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
GL
2021BRD9 TPD Summit Presentation
PU
2021CFT8919 TPD Summit Presentation
PU
2021C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target
MT
2021INSIDER SELL : C4 Therapeutics
MT
2021C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target
MT
2021INSIDER SELL : C4 Therapeutics
MT
2021INSIDER SELL : C4 Therapeutics
MT
1  2  3Next
Upcoming event on C4 THERAPEUTICS, INC.